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Introduction
Breast cancer (BC) is the most frequently diagnosed cancer and the leading cause of cancer-related death in women. HER2-positive BCs display amplification and overexpression of the HER2 tyrosine-kinase receptor gene. This subgroup is defined by aggressive pathological though trastuzumab-based treatments have greatly improved their outcomes over the last decade [1] .
Neoadjuvant treatment is currently administered to patients with locally advanced BC. Beyond increasing the rate of breast-conserving surgery, it serves as a test of in vivo chemosensitivity, and the analysis of residual tumor burden may help understanding resistance to treatments.
The role of tumor-infiltrating lymphocytes (TILs) in BC has been studied in detail over the last decade. Many studies have reported associations between high levels of TILs at diagnosis and better response to neoadjuvant chemotherapy [2] [3] [4] , and better prognosis in both neoadjuvant and adjuvant chemotherapy [5] [6] [7] [8] , particularly for triple negative BCs (TNBC) and HER2-positive BC. Only few studies investigated TILs following neoadjuvant chemotherapy (NAC) and addressed their prognostic significance.
In this study, we assessed the association between TIL levels (before, during, and after NAC) and response to treatment, and their prognostic values in a real-life cohort of HER2-positive BC patients.
Materials and methods

Patients
We analyzed a cohort of 175 T1-3NxM0 patients with HER2-positive invasive BC (NEOREP Cohort, CNIL declaration number 1547270) treated at Institut Curie, Paris, between 2002 and 2012. We included unilateral, non-recurrent, non-inflammatory, non-metastatic tumors, excluding T4 tumors. All patients received NAC, followed by surgery and radiotherapy. NAC regimens changed over time (anthracycline-based regimen or sequential anthracycline-taxane regimen), with trastuzumab used in an adjuvant and/or neoadjuvant setting since 2005. Endocrine therapy (tamoxifen or aromatase inhibitor) was prescribed when indicated. The study was approved by the Breast Cancer Study Group of Institut Curie and was conducted according to institutional and ethical rules regarding research on tissue specimens and patients. Considering that neoadjuvant trastuzumab and adjuvant trastuzumab use have been associated with an increase in pathological complete response (pCR) rates and disease-free survival (DFS), respectively [1] , this study provides data on the subpopulation of patients who received both neoadjuvant and adjuvant trastuzumab as supplementary Materials and methods, available at Annals of Oncology online (supplementary Tables S4-S6 and Figures S6-S10 , available at Annals of Oncology online).
Tumor samples and pathology review
Pretreatment core needle biopsies and post-NAC surgical specimens were reviewed for the purpose of the study and were evaluated independently for the presence of a mononuclear cells infiltrate (including lymphocytes and plasma cells, excluding polymorphonuclear leukocytes) following the recommendations of the international TILs Working Group [9] . TILs were reviewed by one expert breast pathologist (ML) on hematoxylin and eosin-stained sections without additional staining. They were evaluated in the stroma, within the border of the tumor scar, after excluding areas around ductal carcinoma in situ, and tumor zones with necrosis and artifacts, and were scored continuously as the average percentage of stromal area occupied by mononuclear cells. To ensure that the mononuclear cells infiltrate considered as TILs in the analyses indeed corresponded to lymphocytes, we carried out a CD3þ immunostaining on a subset of 20 surgical specimens, which strongly correlated with the levels of unstained TILs (see supplementary Results, Table S3 , and Figures S2-S5 , available at Annals of Oncology online). The scar area was first analyzed and measured at gross examination. Scar appeared as a white aspect of the breast parenchyma representing the previous tumor bed modified by NAC, and is characterized by histiocytes, lymphocytes, macrophages, fibrosis, and elastosis. The whole fibro-inflammatory scar was evaluated on HE sections (size evaluation in millimeters and stromal TILs evaluation). Cases were considered estrogen receptor (ER) or progesterone receptor (PR) positive if at least 1% of the tumor cells expressed estrogen and/or progesterone receptors (ER/PR). Results using a 10% positivity threshold in accordance with guidelines used in France [10] are provided in the Supplementary Materials and methods, available at Annals of Oncology online (supplementary Tables S7-S9 and Figures S11 and S12, available at Annals of Oncology online). HER2 expression was determined by immunohistochemistry and scoring was carried out according to the American Society of Clinical Oncology (ASCO)/College of American Pathologists (CAP) guidelines [11] . Scores 3þ were reported as positive, score 1þ/0 as negative. Tumors with scores 2þ were further tested by FISH. With regard to HER2 gene amplification, an average of 40 tumor cells per sample was evaluated and the mean HER-2 signals per nuclei was calculated. A HER2/CEN17 ratio !2 was considered positive, and a ratio <2 negative [11] .
Study end points ypTN stage was defined according to the American Joint Committee on Cancer.
A pCR was defined as the absence of invasive residual tumor in both breast and axillary nodes (ypT0/is N0). Determination of residual cancer burden (RCB) was realized according to Symmans [12] . DFS was defined as the time from surgery to death, locoregional recurrence or distant recurrence. Patients for whom none of these events were recorded were censored at the date of their last known contact.
Statistical analysis
TIL levels and qualitative variables in classes were compared by ANOVA test with a post hoc Tukey analysis when necessary. Relative changes in TIL levels were calculated by the difference between TIL levels post-and pre-NAC divided by pre-NAC TIL levels. Changes in mean values were investigated in paired t-tests. As no cut-off value for TIL levels after NAC has been published, we investigated the prognostic performance of each threshold value concerning the association with DFS and retained the cut-off value yielding the lowest P-value.
Factors predictive of pCR were introduced into a univariate logistic regression model. A multivariate logistic model with forward stepwise selection procedure was then implemented with the covariates having a likelihood ratio test P-value below 0.10. Survival probabilities were estimated by the Kaplan-Meier method, and survival curves were compared in log-rank tests. Hazard ratios and their 95% confidence intervals were calculated with the Cox proportional hazards model. Variables with a P-value for the likelihood ratio test 0.10 in univariate analysis were included in the multivariate model. Forward selection was used to establish the final multivariate model. The significance threshold was 5%.
Analyses were carried out with R software, version 3.1.2.
Results
A total of 175 patients were included in the cohort. The median age was 47 years (range: 27-78 years), 64% (n ¼ 109) were premenopausal, and 29.1% (n ¼ 51) were overweight or obese (BMI > 25). Clinically, most patients were classified as having stage T2, nodepositive BC (64%, n ¼ 109). Most of the tumors were grade 3 tumors (70%, n ¼ 121), and 38.3% were ER-negative. Most of them received anthracycline-taxane based regimen (88%, n ¼ 154) as neoadjuvant treatment, 82% of patients received both neoadjuvant and adjuvant trastuzumab (n ¼ 144) and 15% adjuvant trastuzumab only (n ¼ 26 Post hoc analyses for significant ANOVA tests (only results with P-value 0.05 or below are reported); baseline TIL levels: larger nodal metastasis (a) size >5 mm versus 2 mm P ¼ 0.05; size >5 mm versus 3-5 mm, P ¼ 0.02; post-NAC TIL levels: RCB (b): 2 versus 0, P < 0.001; 3 versus 0, P < 0.001; 3 versus 1, P < 0.001, 3 versus 2, P < 0.001; mitotic index (c): >22 versus 10, P < 0.001;.tumor cellularity (d): >15% versus 5%, P < 0.001, >15% versus 6-15%, P < 0.001; larger nodal metastasis (e): >5 mm versus 2 mm, P < 0.001; >5 mm versus 3-5 mm, P ¼ 0.03. Bold values indicate P-values equal or lower to 0.05.
At baseline, the median baseline TIL level was 25% (range: 2%-70%). Baseline TIL levels were higher in patients with BMI >25 (P ¼ 0.05) and in patients with larger nodal metastasis >5 mm at NAC completion than patients with larger nodal metastasis 2 mm (P ¼ 0.02) ( Table 1) .
After chemotherapy, the median TIL percentage fell to 10% [TIL levels decrease (n ¼ 136, 78%), unchanged (n ¼ 18, 10%), increase (n ¼ 21, 12%)]. TIL levels decreased in all but three patients in the pCR group ( Figure 1A) . The variation of TIL levels was strongly associated with pCR (P < 10 largest decreases of TILs being strongly associated with the achievement of a pCR ( Figure 1B) . In univariate analysis, baseline TIL levels were not associated with the occurrence of a pCR (supplementary Table S1 , available at Annals of Oncology online).
None of the baseline characteristics of the patients or tumors were significantly associated with post-NAC TIL levels (Table 1) . Conversely, post-NAC TILs were strongly associated with post-NAC parameters, and were higher in tumors with aggressive characteristics [no pCR, high RCB class, high mitotic index and residual tumor cellularity, P < 0.001), as well as a high number of nodes involved (P ¼ 0.054), and larger nodal metastases (P ¼ 0.001)] (Figure 2 ).
Higher RCBs were associated with higher post-NAC TIL levels but not with baseline TIL levels ( Figure 3) . Overall, these findings indicate that the aggressiveness of the residual tumor is associated with TIL levels after chemotherapy, but not with baseline TIL levels. Analyses carried out after stratifying by ER status did not substantially change the results and are detailed in supplementary Table S2 , available at Annals of Oncology online.
During a median follow-up of 38.8 months (range 5.5-91.7), 18 patients suffered relapses (one from pCR group). No association was found between DFS and baseline TIL levels (supplementary Table S3 , available at Annals of Oncology online). In the population of patients without pCR (n ¼ 107), levels of TILs higher than 25% were an independent poor prognostic factor together with BMI, tumor grade, post-NAC mitotic index and RCB score ( Table 2 ; supplementary Figure S1 , available at Annals of Oncology online).
Discussion
This study of 175 HER2-positive pair-matched pre-treatment biopsy and post-treatment surgical specimens provides new insight into TILs variation during NAC, and the prognostic significance of residual TIL levels. First, the association we reported between higher pCR rates and a large decrease in TIL levels after NAC was also found by Ali et al. [13] , who first highlighted that an increase in lymphocyte density was associated with a relative chemoresistance. The higher pCR rate may be due to the disappearance of FOXP3þ lymphocyte-T as suggested by Ladoire et al. [14] .
Second, the clinical significance of post-NAC TILs seems also complex. Here, we showed that (i) at NAC completion, TILs are present at higher levels in tumors failing to reach pCR than in chemosensitive tumors; (ii) this lymphocyte infiltration does not clear cancer cells effectively. Two hypotheses can be drawn. On the one hand, TIL presence in patients with residual disease could be active but may not have had sufficient time to completely eradicate the tumor. Furthermore, the immune response may not recognize the tumor cells and post-NAC TILs could be unable to exert their antitumor function, possibly due to a surrounding immunosuppressive milieu. Interestingly, the opposite pattern has been reported for TNBC by Dieci et al. [15] who showed that high levels of TILs in residual disease were associated with an absence of axillary lymph node metastasis (18 of 27; 66%) and a small tumor size (<2 cm, 22 of 27; 81%) after NAC. Similarly, Miyashita et al. [16] showed that high levels of CD8þ TILs after NAC were associated with a small residual tumor size in a series of 130 TNBCs. An hypothesis accounting for differences in the predictive and prognostic impacts of TILs between HER2-positive BCs and TNBCs is the use of trastuzumab as a neoadjuvant treatment, as interactions between treatment type and the predicted impact of TIL levels have previously been reported [4] . It might also be plausible that TILs significance differs by BC subtype. In TNBC, baseline TIL levels are associated with pCR [2, 4, 17] , whereas this effect seems more controversial in HER2-positive BC [3, [18] [19] [20] , and a non-linear association between TILs and pCR had been evidenced in the NeoSPHERE [18] and the NeoALTTO trials [3] . In our study, TIL levels were not associated with pCR (similarly to the NeoSPHERE [18] , NeoALTTO [3] , and the GeparSepto trials [19] ), whereas they were associated with response to chemotherapy in the GeparQuattro and GeparQuinto [20] trials.
Third, to our knowledge, this is the first report of an adverse prognostic impact of high post-NAC TIL levels in such a large cohort of HER2-positive BC patients. Our findings are consistent with those of Garcia Martinez et al., who reported an association between high levels of post NAC tumor lymphocyte infiltration and a worse DFS, even though the analysis was carried out on 121 patients of various BC subtypes [21] . To end, Ladoire et al. [22] investigated post-treatment tumor lymphocyte infiltrate in 111 HER2-positive BC, and showed that low levels of CD8þ cell infiltration after NAC were associated with poor RFS (HR ¼ 3.85, P < 0.0001), and that low levels of FOXP3þ cell infiltration after NAC were associated with better RFS (HR ¼ 0.52, P ¼ 0.036). We did not yet perform immunostaining to separate out the immune subpopulations, which will enable us to determine whether there is any enrichment in immunosuppressive signaling. However, there is currently no clear consensus as to which single antibody or antibody combination should be used, and their interpretation is not standardized. One advantage of quantitative TIL assessment is that it could be carried out routinely in any pathology department with no real increase in technical costs; furthermore, our findings suggest that this quantitative information per se could be a useful prognostic marker after chemotherapy. Some studies have reported a positive correlation between the numbers of unstained TILs and CD8þ TILs [16] , CD3 counts or counts for other immune subpopulations (CD3þ, CD20þ, CD68þ) [21] , supporting the notion that quantitative assessments could serve as a relevant surrogate marker. Moreover, Denkert et al. [2] showed that the expression of inflammatory marker genes and proteins was linked to the histopathological infiltrate, even for proteins with reported immunosuppressive functions, such as PD-1, PD-L1, IDO1, and CTLA4.
However, from a research standpoint, extensive characterization of the lymphocyte infiltrate remaining in residual tumors to determine the subsets of TILs present will further improve our understanding of chemoresistance mechanisms and anti-tumor immunology. In addition, immunostaining for PD1, PDL1, CTLA4 may provide theranostic information facilitating selection of the patients most likely to benefit from treatment with drugs restoring sensitivity to anti-tumor treatment.
Conclusion
If TILs variations are confirmed to be predictive of pCR, an early assessment of changes in TIL levels during chemotherapy could serve as an early surrogate of resistance to treatment and could offer a possibility to a premature switch to second-line treatments. We will investigate whether the residual lymphocyte infiltrate in non-responding tumor is enriched in immunosuppressive cells that could be targeted by immune checkpoint blockade. If our findings are confirmed, we suggest that patients failing to achieve pCR and with high post-NAC TILS should be included in specific second-line drug trials.
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